Exhibit 2.2
AMENDED AND RESTATED AMENDMENT TO THE MERGER AND SHARE EXCHANGE AGREEMENT
This Amended and Restated Amendment to the Merger and Share Exchange Agreement, dated as of June 30, 2026 (this “Amendment”), by and among Zoar Limited (formerly known as “Dr Ashleys Limited”), a Cayman Islands exempted company limited by shares (“PubCo”), Impact BioMedical, Inc., a Nevada corporation (“Impact”), Dr Ashleys Nevada Sub, Inc., a Nevada corporation (“Merger Sub”), Zoar Labs Limited (formerly known as “Dr Ashleys Bio Labs Limited”), a Cayman Islands exempted company limited by shares (“Zoar Labs”), and Kanans Visvanats (a.k.a. Kannan Vishwanatth), a Latvian national, solely in his capacity as the sole shareholder of the Company (as defined in the Initial Merger Agreement (as defined below)) (“Dr Ashleys Shareholder”). Capitalized terms not otherwise defined in this Amendment shall have the meaning given to them in the Initial Merger Agreement (as defined below).
W I T N E S S E T H:
WHEREAS, PubCo, Zoar Labs, Impact, Merger Sub, and Zoar Shareholder are parties (the “Parties”) to the Merger and Share Exchange Agreement dated as of June 21, 2025 (the “Initial Merger Agreement”);
WHEREAS, the parties previously entered into that certain Amendment No. 1 to the Merger and Share Exchange Agreement, dated as of February 27, 2026 (the “Prior Merger Amendment”); and
WHEREAS, the parties now desire that the Prior Merger Amendment be rescinded, superseded and replaced in its entirety by this Amendment, such that from and after the effectiveness of this Amendment, the Merger and Share Exchange Agreement shall mean the Initial Merger Agreement, as amended only by this Amendment; and
WHEREAS, in accordance with the terms of Section 14.2 of the Initial Merger Agreement, the Parties desire to enter into this Amendment (together with the Initial Merger Agreement, the “Merger Agreement”) to amend the Initial Merger Agreement further as set forth herein to modify certain terms and conditions of the Merger Agreement.
NOW, THEREFORE, in consideration of the foregoing and the respective covenants and agreements set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
SECTION 1. AMENDMENT TO THE MERGER AGREEMENT
1.1 Rescission and Superseding Effect.
(a) The parties hereby acknowledge and agree that that certain Amendment No. 1 to the Merger and Share Exchange Agreement, dated as of February 27, 2026, by and among the parties hereto (the “Prior Merger Amendment”), is hereby rescinded in its entirety and shall be of no further force or effect from and after the effectiveness of this Amendment.
(b) From and after the effectiveness of this Amendment, the rights and obligations of the parties with respect to the subject matter of the Merger Agreement shall be determined solely pursuant to (i) the Transition Arrangement Agreement, dated as of June 21, 2025, as amended only by this Amendment, and (ii) no provision added, deleted, replaced or modified by the Prior Merger Amendment shall have any continuing force or effect unless such provision is expressly set forth in this Amendment.
(c) For the avoidance of doubt, this Amendment is not intended to amend, restate, affirm, ratify or continue the Prior Merger Amendment, but instead is intended to replace the Prior Transition Amendment in its entirety.
(e) Notwithstanding the foregoing, the rescission of the Prior Merger Amendment shall not, in and of itself, invalidate any ministerial act previously taken in reasonable reliance thereon prior to the date hereof; provided, however, that from and after the date hereof no party shall have any further rights or obligations under the Prior Merger Amendment except to the extent, if any, expressly preserved in this Amendment.
1.2. The tenth WHEREAS clause of the Initial Merger Agreement shall be deleted in its entirety and replaced as follows:
“WHEREAS, concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company’s willingness to enter into this Agreement, DSS, Inc., a New York corporation, and its subsidiaries (solely in their capacity as stockholders of Impact) (the “Impact Consenting Stockholders”), collectively holding 92,980,843 Impact Shares on an as-converted basis as of the date of this Agreement, representing 88.87% of the Impact Shares on an as-converted basis, are executing support agreements in favor of the Company in substantially the form attached hereto as Exhibit A (the “Impact Stockholder Voting and Support Agreement”), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of capital stock of Impact (a) to adopt this Agreement and thereby approve the Contemplated Transactions and (b) against any Acquisition Proposal.”
1.3. The definition of “Company Share Consideration” under Section 1.1(a) of the Initial Merger Agreement shall be deleted in its entirety and replaced as follows:
“Company Share Consideration” means 168,076,000 shares of PubCo Ordinary Shares, representing 93.38% of the total issued and outstanding PubCo Ordinary Shares at the Closing.”
1.4. Section 1.1(c) of the Initial Merger Agreement shall be re-designated as Section 1.1(b).
1.5. The following definition shall be inserted immediately after the definition of “Dr Ashleys Shareholder” in Section 1.1(b) of the Merger Agreement.
| …… | |
| DSS Shares | Section 3.2(d) |
| DSS Shares First Batch | Section 3.2(d) |
| DSS Shares Second Batch | Section 3.2(d) |
1.6. Section 2.6(b) of the Initial Merger Agreement shall be deleted in its entirety and replaced with “[Reserved]”:
1.7. Section 2.10 of the Initial Merger Agreement shall be deleted in its entirety and shall be replaced as follows:
“Until the Closing, the Parties agree to retain Vstock Transfer LLC (the “Transfer Agent”) as the “transfer agent” of PubCo, as such term is defined under 12 C.F.R. Part 341, for the purpose of (a) exchanging Impact Shares for PubCo Ordinary Shares in accordance with Section 2.6(a) and (b) issuing the Company Share Consideration, Compensation Shares, DSS Shares and BMI Closing Shares in accordance with Section 3.2. The Transfer Agent shall (i) exchange each Impact Share for the Merger Consideration, (ii) issue the Company Share Consideration, Compensation Shares and DSS Shares, and (iii) take or cause to be taken such actions as are necessary to update PubCo’s register of security holders to reflect the actions contemplated by clauses (i) and (ii) of this sentence, in each case in accordance with the terms of this Agreement and, to the extent applicable, the Articles of Merger, the NRS customary transfer agent procedures and the rules and regulations of the Depository Trust Company (“DTC”), in each case in a form approved by the Company.”
1.8. Section 3.2(d) of the Initial Merger Agreement shall be deleted in its entirety and replaced as follows:
“(d) PubCo shall issue to Frank D. Heuszel, the Chief Executive Officer of Impact, a total of 22,000 shares of PubCo Ordinary Shares (“Compensation Shares”), and to DSS, Inc., 53,000 PubCo Ordinary Shares (the “DSS Shares First Batch”) and 75,000 PubCo Ordinary Shares (the “DSS Shares Second Batch,” together with the “DSS Shares First Batch,” the “DSS Shares”) at the Closing. Subject to the effectiveness of the Registration Statement, upon issuance, such Compensation Shares and DSS Shares shall be registered and freely tradable by the respective holder(s) under the Securities Act, subject only to any restrictions imposed by any applicable laws or regulations.”
1.9 Section 5.9 of the Initial Merger Agreement shall be deleted in its entirety and replaced as follows and Schedule 5.9 of the Company Disclosure Schedule as set forth in Exhibit A hereto will be inserted into the Company Disclosure Schedule:
“5.9. Absence of Undisclosed Liabilities. Since, except for the liabilities as disclosed in Schedule 5.9 of the Company Disclosure Schedule, the Company and its Subsidiaries do not have any liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of any kind, whether accrued, absolute, contingent, matured, unmatured or otherwise (each a “Liability”), in each case, of a type required to be reflected or reserved for on a balance sheet prepared in accordance with GAAP, except for (i) Liabilities or obligations specifically disclosed, reflected or reserved against in the Company Financials; (ii) Liabilities incurred in the Ordinary Course of Business since the date of the Company Financials; (iii) Liabilities to perform under Contracts entered into by the Company or its; (iv) Liabilities incurred in connection with the Contemplated Transactions; and (v) Liabilities that would not be reasonably expected to have, individually or in the aggregate, a Company Material Adverse Effect.
1.10. Section 5.15(a) of the Initial Merger Agreement shall be deleted in its entirety and replaced as follows and Schedule 5.15(a) of the Company Disclosure Schedule as set forth in Exhibit B hereto will be inserted into the Company Disclosure Schedule:
“(a) Except as set forth in Schedule 5.15(a) of the Company Disclosure Schedule, there is no pending Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves the Company or any of its Subsidiaries or any Company Associate (in his or her capacity as such) or any of the material assets owned or used by the Company or any of its Subsidiaries or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.”
1.11. Section 6.7(d) of the Initial Merger Agreement shall be deleted in its entirety and replaced as follows:
“6.7. PubCo Activities. Since its formation, other than activities described in Schedule 6.7 of the PubCo Disclosure Schedule, PubCo (a) has not engaged in any business activities other than as contemplated by this Agreement, (b) has not owned directly or indirectly any ownership, equity, profits or voting interest in any Person, (c) other than fees in respect of its incorporation, has not had any assets or Liabilities except those incurred in connection with this Agreement and the Ancillary Documents to which it is a party and the Transactions and other de minimis assets or Liabilities, and (d) other than its Organizational Documents, this Agreement and the Ancillary Documents to which it is a party, has not been party to or bound by any Contract.”
1.12 The document as set forth in Exhibit C hereto shall be inserted into Schedule 5.2 of the Company Disclosure Schedule
.
1.13 The document as set forth in Exhibit D hereto shall be inserted into Schedule 6.2 of the PubCo Disclosure Schedule.
1.14 Schedule 6.7 of the PubCo Disclosure Schedule as set forth in Exhibit E hereto shall be inserted into the PubCo Disclosure Schedule,
1.15 Section 13.1(b) of the Initial Merger Agreement shall be deleted in its entirety and replaced as follows:
“(b) by either Impact, PubCo, Dr Ashleys Shareholder, or the Company if the Contemplated Transactions shall not have been consummated by July 1, 2026 (the “End Date”) which may be extended with the mutual written consent of Impact, PubCo, Dr Ashleys Shareholder and the Company; provided, however, that the right to terminate this Agreement under this Section 13.1(b) shall not be available if action or failure to act of such Party or such Party’s Subsidiaries has been a principal cause of the failure of the Contemplated Transactions to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement;”.
1.16 Section 7.15(a) of the Initial Merger Agreement shall be deleted in its entirety and replaced as follows and Schedule 7.15(a) of the Impact Disclosure Schedule, as set forth in Exhibit F hereto, shall be inserted into the Impact Disclosure Schedule:
“(a) Except as set forth on Section 7.15(a) of the Impact Disclosure Schedule, there is no pending Legal Proceeding and to the Knowledge of Impact, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves Impact or any of its Subsidiaries or any Impact Associate (in his or her capacity as such) or any of the material assets owned or used by Impact or any of its Subsidiaries or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.”
SECTION 2. EFFECTIVENESS OF AMENDMENT
Upon the execution and delivery hereof, the Prior Merger Amendment shall be rescinded and superseded in its entirety as set forth in Section 1.1 of this Amendment, and the Initial Merger Agreement shall thereupon be deemed to be amended as set forth herein and with the same effect as if the amendments made hereby were originally set forth in the Initial Merger Agreement. This Amendment and the Initial Merger Agreement shall henceforth respectively be read, taken and construed as one and the same instrument, but such amendment shall not operate so as to render invalid or improper any action heretofore taken under the Initial Merger Agreement. Upon the effectiveness of this Amendment, each reference in the Merger Agreement to “this Agreement,” “hereof,” “hereunder” or words of like import referring to the Merger Agreement shall refer to the Merger Agreement as amended by this Amendment.
SECTION 3. GENERAL PROVISION
1.8. Miscellaneous. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the parties hereto and delivered to the other parties, it being understood that all parties need not sign the same counterpart. This Amendment may be executed and delivered by facsimile or PDF transmission. The terms, agreements and provisions of Section 14 of the Initial Merger Agreement shall apply to this Amendment, as applicable.
1.9. Merger Agreement in Effect. Except as specifically and explicitly provided for in this Amendment, the Initial Merger Agreement shall remain unmodified and in full force and effect.
[Signature Page Follows]
WHEREOF, the Parties have caused this Amendment to be executed as of the date first above written.
| IMPACT BIOMEDICAL INC. | ||
| By: | ||
| Name: | Frank D. Heuszel | |
| Title: | Chief Executive Officer | |
IN WITNESS WHEREOF, the Parties have caused this Amendment to be duly executed as of the date first above written.
| ZOAR Limited | ||
| By: | ||
| Name: | Daphne Y. Huang | |
| Title: | Chief Executive Officer | |
IN WITNESS WHEREOF, the Parties have caused this Amendment to be duly executed as of the date first above written.
| ZOAR LABS LImited | ||
| By: | ||
| Name: | Daphne Y. Huang | |
| Title: | Chief Executive Officer | |
WHEREOF, the Parties have caused this Amendment to be executed as of the date first above written.
| DR ASHLEYS NEVADA SUB, INC. | ||
| By: | ||
| Name: | Daphne Y. Huang | |
| Title: | Chief Executive Officer | |
IN WITNESS WHEREOF, the Parties have caused this Amendment to be duly executed as of the date first above written.
| Dr. Ashley SHAREHOLDER | ||
| By: | ||
| Name: | Kanans Visvanats | |